Skip to content
Allegro Ophthalmics - From Theory to Therapy
  • About
    • Company
    • Management
    • Board of Directors
    • Scientific Advisors
  • Science
  • Pipeline
    • Pipeline
    • Risuteganib
    • ALG-1007
    • Clinical Trials
  • Therapeutic Areas
    • Dry AMD
    • Dry Eye Disease
  • News
    • Press Releases
    • Allegro in the News
    • Events

The Latest Data on Anti-Integrin Therapy for Patients with DME

Posted on December 1, 2017 | by Allegro Ophthalmics, LLC

In a phase 2b study, ALG-1001 showed additional efficacy in patients who had plateaued on chronic anti-VEGF therapy.

To read the full article please visit Retina Today: “The Latest Data on Anti-Integrin Therapy for Patients with DME”

 

Posted in News Features
Allegro Ophthalmics - From Theory to Therapy

Setting the pace in ocular care
Read More >

Allegro Ophthalmics LLC
31473 Rancho Viejo Road, Suite 204
San Juan Capistrano, CA 92675, USA

Phone: +1 949.940.8130
Email: info@allegroeye.com

RECENT NEWS

Allegro Ophthalmics Announces Presentation of Key Data Surrounding Dry AMD Pipeline Candidates, Treatment Considerations
February 10, 2023

  • About
  • Science
  • Pipeline
  • Therapeutic Areas
  • News
  • Careers
  • Contact Us
© 2023 Allegro Ophthalmics, LLC. All rights reserved. | Privacy Policy | Terms of Use